Sanofi S.A. (NASDAQ/Euronext Paris: SNY / SAN.PA) - Deep Dive

Research note prepared 2026-06-17. No valuation, no price targets. All figures sourced to filings, press releases, and earnings calls.

Section 1: What the Company Does

Sanofi is a French pharmaceutical company that discovers, makes, and sells prescription medicines and vaccines. Strip away the jargon and the business is two things: (1) a large immunology franchise built around one enormous drug, Dupixent, plus a growing roster of newer launch products in rare diseases, oncology, and immunology; and (2) one of the four big global vaccine makers, with franchises in RSV prevention for infants, influenza, meningitis, and childhood immunization.

As of 2026, Sanofi describes itself as a "pure-play biopharma." That label is recent and it matters. For most of its life Sanofi was a sprawling conglomerate spanning patented drugs, a giant diabetes business (it invented and sold Lantus, the world's best-selling insulin for years), generics, animal health, and a large consumer-health arm selling household names like Allegra, Doliprane, and Dulcolax. Over the last decade management methodically dismantled that conglomerate. Animal health (Merial) was swapped to Boehringer Ingelheim in 2017. The diabetes and cardiovascular research engine was deprioritized in 2019 when Paul Hudson became CEO and announced "Play to Win," a strategy that bet the company on specialty care and vaccines and walked away from chasing me-too diabetes drugs. The final and largest piece came on April 30, 2025, when Sanofi sold a 50% controlling stake in its consumer-health business, Opella (the Allegra/Doliprane unit), to private-equity firm CD&R for around €10 billion of net cash proceeds, retaining a 48.2% minority stake (Sanofi/CD&R close, Apr 30 2025).

The core value proposition is straightforward but hard to execute: solve diseases where existing treatments fail, and protect populations from infection. The economic engine is the patent. Sanofi spends roughly €7 billion a year on R&D to discover a molecule, runs it through a decade of clinical trials and regulatory review, and if it works the company earns a temporary government-granted monopoly to sell it. During that window the drug can generate billions a year at very high gross margins because the marginal cost of a biologic vial is tiny relative to its price. The whole company is a machine for converting R&D spend and acquisitions into patent-protected revenue streams, and then defending and extending those patents (new indications, new formulations) for as long as possible before generics or biosimilars arrive.

The flagship example is Dupixent. It is an injected antibody (developed jointly with Regeneron) that blocks two signaling proteins, IL-4 and IL-13, which drive type-2 inflammation. A patient with severe eczema (atopic dermatitis) whose skin will not clear on steroids injects Dupixent every two weeks; over months the inflammation subsides. The clever part of the business is that the same underlying inflammation drives many different diseases, so Sanofi has kept running trials to add indication after indication onto the same molecule: asthma, nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), bullous pemphigoid, and most recently a regulatory filing for allergic fungal rhinosinusitis (the ninth indication). Each new indication unlocks a new patient pool without the cost of inventing a new drug. Dupixent reached €15.7 billion in sales in 2025, up 25%, with patient numbers up more than 30% (Q4 2025 call, Jan 29 2026).

The central tension that defines Sanofi right now is also captured by one fact: Dupixent's key patents begin to expire in the early 2030s. The entire strategic debate inside the company - and the reason its CEO was replaced in February 2026 - is about what replaces Dupixent.

Paul Hudson, CEO 2019-2026, argued that "doubling down on the company's pipeline" would turn Sanofi into a research powerhouse, an approach that, in the words of reporting on his ouster, "sometimes worried investors" (STAT News, Feb 12 2026).

Section 2: Business Segments

Following the Opella divestment, Sanofi reports as essentially a two-engine company: Biopharma (Pharma/Specialty Care) and Vaccines. There is also a third, now-financial rather than operational, piece: the retained 48.2% stake in Opella, which is no longer consolidated as an operating segment but sits on the balance sheet and in associate income. Because the company manages Pharma across therapeutic areas (Immunology, Rare Disease, Oncology, Neurology), I treat those as sub-franchises within Biopharma rather than separate reporting segments.

2.1 Biopharma (Pharma / Specialty Care)

What it does. This is the prescription-medicine engine and the overwhelming majority of group sales (Biopharma net sales were roughly €19.9 billion in H1 2025 alone, growing ~10% at constant rates per the H1 2025 6-K). It is organized around four therapeutic areas. Immunology is the crown jewel and is dominated by Dupixent, with a second wave forming behind it: amlitelimab (an OX40-Ligand antibody for atopic dermatitis with monthly/quarterly dosing) and rilzabrutinib (Wayrilz, a BTK inhibitor launched in 2025 for immune thrombocytopenia and other immune diseases). Rare Disease spans hemophilia (ALTUVIIIO, a long-acting factor VIII therapy that crossed €1.2 billion in 2025 and reached blockbuster status; Fitusiran/Qfitlia, an RNAi therapy launched in 2025), Pompe disease (Nexviazyme), and the legacy Genzyme rare-disease portfolio (Gaucher, Fabry). Oncology centers on Sarclisa (an anti-CD38 antibody for multiple myeloma) and, since the 2025 Blueprint Medicines acquisition, Ayvakit (avapritinib for systemic mastocytosis), which was a top growth driver in Q1 2026. Neurology is the area that just took a public hit: tolebrutinib, a BTK inhibitor for multiple sclerosis, failed its primary endpoint in primary progressive MS and is now limited to a secondary-progressive MS regulatory path in the EU only.

Core capability. What Biopharma knows how to do that is genuinely hard is type-2 inflammation biology and antibody/large-molecule drug development at global scale. The Dupixent indication-expansion playbook - taking one validated mechanism and methodically proving it across a dozen distinct diseases through large, expensive Phase 3 trials - is a capability built over fifteen-plus years (Regeneron and Sanofi's antibody collaboration dates to 2007). Manufacturing biologics consistently at billions of doses, holding the regulatory relationships across the FDA, EMA, and dozens of national regulators, and running a specialty salesforce that calls on dermatologists, pulmonologists, and allergists worldwide are all things a new entrant cannot stand up quickly.

Why it exists as a unit. Specialty care has fundamentally different economics from the old primary-care Sanofi: fewer patients, far higher price per patient, prescribed by specialists rather than GPs, and protected by biologic patents and biosimilar-resistance (large molecules are much harder to copy than small-molecule pills). Hudson's "Play to Win" pivot in 2019 was explicitly about exiting low-margin primary care to concentrate here.

Competitive position. In atopic dermatitis Dupixent competes against AbbVie's Rinvoq, Eli Lilly's Ebglyss, and Pfizer's Cibinqo (the latter two are oral JAK inhibitors). Dupixent wins on safety (no JAK black-box warning) and on its breadth of approved indications; it loses on convenience to oral pills. In multiple myeloma Sarclisa competes against J&J's much larger Darzalex. Biopharma is the group's growth engine and margin engine simultaneously.

Group fit. This is where management directs capital and where the future of the company is decided. Every acquisition of 2025 (Blueprint, Vicebio) fed this segment.

2.2 Vaccines

What it does. Sanofi is one of the four global-scale vaccine companies (with GSK, Merck, and Pfizer). Full-year 2025 vaccine sales were €7.9 billion. The franchise has four pillars: RSV prevention via Beyfortus (nirsevimab, an antibody co-developed with AstraZeneca that protects infants through their first RSV season; €1.8 billion in 2025, +9.5%, "protecting over 11 million babies globally"); influenza (Fluzone/Flublok high-dose franchise, gaining U.S. share); meningitis (Menactra, MenQuadfi); and childhood/booster vaccines (polio, pertussis, the Vaxelis pediatric combination). In 2025 Sanofi also launched Nuvaxovid (a protein-based COVID vaccine, partnered with Novavax) and is acquiring Dynavax (Heplisav-B hepatitis-B vaccine, expected to close Q1 2026), which contributed to Q1 2026 growth.

Core capability. Vaccine manufacturing is a different and arguably harder industrial discipline than pills: live or recombinant biological production, cold-chain logistics, multi-year capacity planning against unpredictable demand (flu strain composition changes annually; RSV is seasonal), and deep relationships with government and public-health buyers. Beyfortus in particular required scaling antibody manufacturing to tens of millions of infant doses in a single season.

Why it exists as a unit. Vaccines is a fundamentally different customer (governments, public-health agencies, pediatricians administering to healthy people, not specialists treating sick patients), different regulatory regime, different seasonality, and different manufacturing footprint. It has always been run as a distinct business (formerly Sanofi Pasteur).

Competitive position. Against GSK (Arexvy RSV vaccine for older adults; Shingrix), Pfizer (Abrysvo RSV; Comirnaty COVID), Merck (Gardasil, pneumococcal), and Moderna (mRNA). Beyfortus's edge is that it is a long-acting antibody given once per season to infants rather than a vaccine, and it captured the new infant-RSV market alongside Pfizer's maternal vaccine. The franchise's exposure is that influenza demand is volatile (Q3 2025 vaccine sales fell 7.8% on lower flu) and COVID demand has collapsed from pandemic peaks.

Group fit. Vaccines is the cash-generative, steady, and somewhat lower-growth ballast against the higher-growth Biopharma engine. Management guided that vaccine sales will "slightly decline in 2026" partly due to ~€200 million of portfolio-optimization divestments (Q4 2025 call, Jan 29 2026).

Segment summary

Section 3: Products and Business Detail

Immunology. Dupixent (dupilumab) is the franchise. Approved across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, and bullous pemphigoid, with a regulatory filing accepted in the US for allergic fungal rhinosinusitis (the ninth indication, per the Q4 2025 call). It is co-owned with Regeneron, which shares in worldwide profits - an important economic nuance because Sanofi books the global sales but splits the economics. The second-wave immunology pipeline is amlitelimab (anti-OX40L, positive Phase 3 in atopic dermatitis with "progressively increasing efficacy over time, no plateau through week 24-52," and the key convenience pitch of monthly or quarterly dosing) and rilzabrutinib (Wayrilz, an oral BTK inhibitor launched in 2025), plus brivekimig (a TNF-alpha/OX40L bispecific in development for inflammatory bowel disease).

Rare Disease. ALTUVIIIO (efanesoctocog alfa) is a long-acting factor VIII replacement for hemophilia A, blockbuster status reached in 2025 (€1.2 billion), mostly US-driven. Qfitlia (fitusiran) is an RNAi therapy launched in 2025 for hemophilia. The legacy Genzyme franchise covers Pompe (Nexviazyme/Lumizyme), Gaucher (Cerezyme), and Fabry (Fabrazyme) - durable orphan-disease cash flows. Tzield (teplizumab) delays type-1 diabetes onset.

Oncology. Sarclisa (isatuximab, anti-CD38) for multiple myeloma. Ayvakit/Ayvakyt (avapritinib) for systemic mastocytosis and GIST, acquired with Blueprint Medicines in 2025 and an immediate top-three growth driver by Q1 2026.

Neurology. Tolebrutinib - BTK inhibitor; failed primary-progressive MS, EU regulatory review limited to secondary-progressive MS only.

Vaccines. Beyfortus (nirsevimab, RSV monoclonal for infants, with AstraZeneca); Fluzone High-Dose / Flublok (influenza); Menactra / MenQuadfi (meningitis); Vaxelis (pediatric hexavalent); polio and pertussis franchises; Nuvaxovid (protein COVID vaccine, with Novavax, launched 2025); and Heplisav-B (hepatitis B, arriving via the pending Dynavax acquisition).

Manufacturing. Sanofi runs biologics and vaccine plants across France, Germany, the US, and other geographies. Biologics (Dupixent, ALTUVIIIO, Sarclisa) require living-cell bioreactor production, multi-month batch cycles, and exacting regulatory validation; vaccine plants run seasonal antibody and recombinant-protein lines requiring multi-year capacity commitments. Capacity for Beyfortus and Dupixent has been a recurring scaling theme. Management has repeatedly flagged "minimal tariff impact" and "gross margin expansion" continuing as the mix shifts toward high-margin specialty biologics (Q4 2025 call, Jan 29 2026).

Geographies. The US is the dominant and fastest-growing market - H1 2025 US net sales were €9.5 billion, up ~16% at constant rates, driven by Dupixent, the launch portfolio, and a temporary Lantus demand bump (H1 2025 6-K). Europe and rest-of-world follow. The US skew is both an opportunity (premium pricing) and a concentration risk (drug-pricing politics, tariffs, IRA negotiation).

Milestones that reshaped the business. 2017 Merial animal-health swap to Boehringer; 2018 Bioverativ (hemophilia) and Ablynx acquisitions; 2019 "Play to Win" pivot under Hudson, deprioritizing diabetes/CV research; 2025 Opella consumer-health divestment (→ pure-play biopharma); 2025 acquisition spree (Blueprint Medicines, Vicebio, pending Dynavax) funded partly by the ~€10 billion Opella proceeds; February 2026 CEO change.

Section 4: Customers

Sanofi serves two very different buyers, one per segment.

For Biopharma, the buyers are specialist physicians and the payers behind them. A dermatologist, pulmonologist, allergist, hematologist, or oncologist writes the prescription; the actual payer is an insurer, a national health system, or a US pharmacy-benefit manager. The decision criteria are clinical efficacy and safety data, guideline placement, and - increasingly - net price after rebates. Switching costs are high at the patient level: a patient stable on Dupixent for severe eczema is clinically reluctant to switch, and physicians are conservative once a patient responds. But switching costs are low at the new-patient level, where the next launch (an oral JAK, Lilly's Ebglyss, amlitelimab) competes head-on for each new diagnosis. Sales cycles are years (driven by guideline updates and formulary cycles), not transactions. Concentration is by product, not customer: Dupixent is so large that the franchise's health depends on a single molecule's lifecycle far more than on any one account.

For Vaccines, the buyers are governments, public-health agencies, and large institutional purchasers. A national immunization program, the US CDC's pediatric vaccine purchasing, GAVI for low-income countries, and pediatric practices. These are tender-driven, volume-based, multi-year procurement relationships with strong recurring characteristics (annual flu reorders, seasonal Beyfortus stocking). The decision-maker is a public-health committee weighing efficacy, supply reliability, and cost-per-dose. Switching is governed by recommendation bodies (ACIP in the US); a favorable or unfavorable committee vote can swing a franchise overnight, which is both the moat (incumbency once recommended) and the risk.

Contract structure and revenue predictability. Biopharma is a mix of recurring chronic-therapy revenue (patients on Dupixent for years) and growth from new launches and indications - reasonably predictable in aggregate but exposed to patent cliffs at the molecule level. Vaccines is more lumpy and seasonal (flu mix changes yearly; RSV is one season) but with sticky government relationships. The clearest concentration risk in the whole company is Dupixent: a drug generating roughly a third of group sales whose patents begin expiring in the early 2030s.

Section 5: Competitive Landscape

Big pharma is an oligopoly of roughly 15 global-scale players competing therapeutic area by therapeutic area rather than as monolithic companies. Sanofi competes in three arenas at once.

In type-2 immunology / atopic dermatitis, Dupixent's direct rivals are AbbVie's Rinvoq (oral JAK), Eli Lilly's Ebglyss (an IL-13 biologic positioned as a cleaner once-monthly competitor), and Pfizer's Cibinqo (oral JAK). Dupixent wins on its safety profile (biologics avoid the JAK class's boxed cardiovascular/thrombosis warnings) and on the sheer breadth of its approved indications, which no rival matches. It is exposed on convenience (an injection versus a daily pill) and on the early-2030s patent cliff. Note that Regeneron is a partner, not a competitor, on Dupixent - the two share global profits.

In vaccines, the rivals are GSK (Arexvy adult-RSV, Shingrix), Pfizer (Abrysvo RSV, Comirnaty), Merck (Gardasil, pneumococcal), and Moderna (mRNA platform). Beyfortus's edge is being the established once-per-season infant-RSV antibody; its exposure is ACIP/recommendation risk and volatile flu/COVID demand.

In oncology and rare disease, Sarclisa competes against J&J's far larger Darzalex in multiple myeloma; hemophilia products face Roche's Hemlibra, Novo Nordisk, Pfizer, and BioMarin's gene therapy.

Barriers to entry are among the highest in any industry: a new molecule costs well over a billion dollars and a decade to bring to market, biologics are extremely hard to copy (biosimilars take years and capital), and the regulatory and salesforce infrastructure is enormous. But the barriers protect incumbency in general, not any single product - patents expire on schedule, and a competitor with a better molecule in the same indication can take share among new patients. Sanofi is strong where it has biologic franchises with indication runway (Dupixent today, amlitelimab and the launch portfolio tomorrow) and exposed where a single product dominates the P&L.

(Market caps are peer-size references only, with as-of dates; they move and are not applied to Sanofi.)

Section 6: Industry

Demand drivers. Pharma demand is driven by aging populations, the rising prevalence of chronic inflammatory and metabolic disease, the expansion of biologics into ever more indications, and public-health vaccination programs. It is one of the most defensive end-markets in the economy: people take prescription medicines and immunize children regardless of the business cycle. The growth in Sanofi's specific niches - type-2 inflammation, rare disease, infant RSV prevention - comes from expanding the treatable patient pool (new indications, newly recommended vaccines) rather than from macroeconomic growth.

Size and trajectory. The global pharmaceutical market is well over $1.5 trillion in annual sales and grows mid-single digits structurally, with biologics and specialty care growing faster than the small-molecule average. The largest companies by market value as of early-to-mid 2026 are Eli Lilly (~$1.5T, lifted by obesity/diabetes drugs), J&J (~$489B), AbbVie (~$388B), AstraZeneca (~$316B), and Novartis (~$293B) (Statista/Motley Fool largest-pharma 2026). Within this, Sanofi sits as a mid-pack large-cap whose relative valuation has lagged peers - one reason the board acted on leadership.

Regulation is the industry. Every product requires FDA/EMA/national approval; vaccines additionally require recommendation-body endorsement (ACIP). Patents and regulatory exclusivity define the revenue window; biosimilar and generic entry ends it. In the US the Inflation Reduction Act introduced Medicare price negotiation, a structural headwind that can compress the back-end economics of large drugs. Tariffs on pharmaceutical imports have become a live policy risk; Sanofi management has repeatedly characterized the direct tariff impact as minimal but the topic recurs on every recent call.

Cyclicality. Low. The industry is counter-cyclical to defensive. The real "cycles" are product cycles (launch ramp → peak → patent cliff) and, for vaccines, seasonal demand (flu strain mix, RSV season) plus the post-pandemic COVID normalization that has been a multi-year headwind.

Tailwinds: biologics indication expansion, infant-RSV market creation, aging demographics, pipeline-rich rare disease. Headwinds: US drug-pricing politics (IRA negotiation), pharma tariffs, biosimilar/patent-cliff erosion of mature franchises, and volatile vaccine demand.

Section 7: Growth Triggers

All items below are forward-looking statements made by management on the named calls.

• Dupixent ninth indication - allergic fungal rhinosinusitis (AFRS). US regulatory acceptance announced; a new patient pool on the existing molecule. (Q4 2025 call, Jan 29 2026)

• Amlitelimab launch in atopic dermatitis. Positive Phase 3 data with monthly/quarterly dosing positioned as the next immunology pillar.

  "Progressively increasing efficacy over time, with no evidence of plateau through week 24-52." (Q4 2025 call, Jan 29 2026)

• New 2025 launches ramping into 2026 - Qfitlia, Wayrilz, Nuvaxovid (joining ALTUVIIIO and Ayvakit), described as collectively generating €5.7 billion in 2025 launch sales with substantial runway. (Q4 2025 call, Jan 29 2026; pharma-launch growth reiterated Q1 2026 call, Apr 23 2026 - launches +49.6% to €1.2B)

• Dynavax (Heplisav-B) acquisition closing. Expected to close in Q1 2026, adding a hepatitis-B vaccine to the franchise; already cited as a Q1 2026 vaccine contributor. (Q4 2025 call, Jan 29 2026; Q1 2026 call, Apr 23 2026)

• External growth / M&A firepower of €14-15 billion earmarked for further bolt-on acquisitions while maintaining balance-sheet flexibility, after Blueprint and Vicebio in 2025. (Q4 2025 call, Jan 29 2026)

• Multi-year profitable growth ambition. Management committed to "high single-digit growth in sales" with business EPS "slightly faster than sales" for 2026, and a longer ambition of profitable growth "over at least five years" and "earnings growth into the next decade." (Q4 2025 call, Jan 29 2026)

  "We have the ambition to pursue earnings growth into the next decade." (paraphrased from Q4 2025 call)

• Pipeline depth as a forward engine: 12 Phase 3 readouts and 15 Phase 2 readouts delivered in 2025, with 10 new molecules entering Phase 1 (including three gene therapies); 77 clinical-stage projects, 34 in Phase 3 or submitted as of April 2026. (Q4 2025 call, Jan 29 2026; Sanofi pipeline page, April 2026)

Section 8: Key Risks

1. The Dupixent patent cliff (high-probability, high-impact, but timed). Dupixent is roughly a third of group sales and its key patents begin expiring in the early 2030s. The entire bull thesis depends on the second wave (amlitelimab, the launch portfolio, the pipeline) filling the hole before biosimilars erode the franchise. This is not a question of if but of whether the replacements arrive in time and at sufficient scale. It is the single most important fact about the company, and it was the explicit subtext of the CEO change.

2. Pipeline execution risk, made vivid by tolebrutinib. Sanofi's strategy is R&D-heavy: spend now to invent the next Dupixent. When a major bet fails, the market punishes it. Tolebrutinib failed its primary endpoint in primary-progressive MS, collapsing what had been a marquee neurology opportunity to an EU-only secondary-progressive path. Clinical setbacks like this were cited among the reasons for Hudson's removal (STAT News, Feb 12 2026). Mechanism: each high-profile Phase 3 miss both removes a future revenue line and undermines confidence in the pipeline-first strategy.

3. CEO transition and strategic uncertainty (live, near-term). The board ousted Paul Hudson in February 2026 despite strong reported financial results, replacing him with Belén Garijo (ex-Merck KGaA CEO, ex-Sanofi). New CEOs often reset strategy, rebase guidance, take impairments, or change capital allocation.

Hudson's pipeline-first approach "sometimes worried investors," and the board acted on "recent clinical setbacks and investor concerns about his strategy" (STAT News, Feb 12 2026). The risk is twofold: execution disruption during the handover (Olivier Charmeil ran the company on an interim basis through the Q1 2026 call), and the possibility that the new CEO's strategy diverges from the one underpinning current guidance.

4. US concentration plus drug-pricing and tariff politics. With US net sales the dominant and fastest-growing region (~16% growth in H1 2025), Sanofi is heavily exposed to US policy: IRA Medicare price negotiation could eventually capture large products, and pharmaceutical tariffs are a recurring live threat. Management has framed tariff impact as minimal, but the topic surfaces on every recent call - a sign of genuine uncertainty.

5. Vaccine demand volatility and recommendation risk. Flu demand swings (Q3 2025 vaccines fell 7.8% on lower flu sales), COVID demand has structurally collapsed, and any single ACIP recommendation can swing a franchise. Management itself guided vaccines to "slightly decline in 2026." Mechanism: vaccines are the supposed ballast, but they are lumpier than the label suggests.

6. Regeneron dependency on the flagship. Dupixent's economics are shared with Regeneron. Sanofi does not fully own its most important asset, which caps the upside it captures and ties a third of the business to a partnership.

Section 9: Walk the Talk

The six calls used: Q4 FY2024 (Jan 30 2025), Q1 2025 (Apr 24 2025), Q2/H1 2025 (Jul 31 2025), Q3 2025 (Oct 24 2025), Q4 FY2025 (Jan 29 2026), and Q1 2026 (Apr 23 2026). The most recent is within 90 days of today. The first five were hosted by CEO Paul Hudson; the sixth (Q1 2026) was hosted under interim leadership after Hudson's ouster, with Belén Garijo formally taking over April 29 2026.

The striking thing about Sanofi management's credibility over these six quarters is that they consistently delivered on, and even exceeded, the financial numbers - and the CEO was fired anyway. That paradox is the whole story.

Start with the oldest call. On Jan 30 2025 (Q4 FY2024), Hudson reported full-year sales of €41.1 billion (+11.3% CER), said Dupixent had surpassed its €13 billion target growing 23%, announced a €3.92 dividend (30th consecutive increase) and a €5 billion 2025 buyback, and guided 2025 sales to "mid-to-high single-digit" growth at CER.

Q4 2024 guidance: 2025 sales "anticipated to grow by a mid-to-high single-digit percentage at CER."

By Q1 2025 (Apr 24 2025) the company delivered +9.7% CER with Dupixent +20.3%, and the pipeline produced six regulatory approvals - tracking ahead of guidance. By Q2/H1 2025 (Jul 31 2025), management did something credible: they raised full-year sales guidance to "high single digits" and reaffirmed low-double-digit EPS growth despite explicit FX and flu headwinds, with H1 EPS already up 12%. That is a management team beating and raising, not sandbagging then missing.

Q2 2025: management "raised full-year sales guidance to high single digits and reaffirmed low double-digit EPS growth despite FX and flu headwinds."

Q3 2025 (Oct 24 2025) showed the mixed reality underneath the headline: group sales +7.0% CER, Dupixent crossing €4 billion in a single quarter for the first time - but vaccines down 7.8% on lower flu, exactly the headwind they had flagged. They told you it was coming, and it came. That is consistent, not erratic.

Then Q4 FY2025 (Jan 29 2026), Hudson's final call, was the strongest of the lot: full-year sales €43.6 billion (+9.9% CER), Q4 +13.3%, Dupixent at €15.7 billion (+25%), business EPS +15% including buybacks, free cash flow €8.1 billion (18.5% of sales). The dividend rose to €4.12 (31st consecutive increase). On the metrics they had set themselves a year earlier, they over-delivered. He then set the 2026 bar at "high single-digit" sales growth and reiterated the multi-year ambition.

Two weeks later, on Feb 11 2026, the board declined to renew his mandate. The Q1 2026 call (Apr 23 2026) - delivered under interim leadership - then reported +13.6% CER sales growth, the strongest start in years, with Dupixent +30.8% and launches +49.6%. The numbers Hudson's strategy produced kept beating after he was gone.

So what did management not deliver? The failures were in the pipeline and in the share price, not in the guidance. Tolebrutinib, repeatedly discussed as a neurology growth pillar across 2025, failed primary-progressive MS and was quietly downgraded to an EU-only secondary-progressive path by the Q4 2025 call. And the broader bet - "doubling down on the pipeline" to manufacture a research powerhouse - cost margin and worried investors enough that the board lost patience even as revenue compounded. The promise that was kept was financial; the promise that was effectively rejected was strategic.

Assessment: On the numbers, this is a management team that did what it said and then beat it - consistent, transparent about headwinds, and not prone to overpromising on guidance. The credibility gap is strategic, not numerical: the R&D-first bet to replace Dupixent generated genuine pipeline disappointments (tolebrutinib) and lagging relative valuation, and the board judged that a strong P&L was not buying enough strategic confidence. The reader should weight the financial track record as reliable and treat the forward strategy as genuinely unsettled until Belén Garijo sets her own course.

Section 10: Shareholder Friendliness Index

Dividends. Sanofi raised its dividend in each of the last three years: €3.76 for FY2023, €3.92 for FY2024 (the 30th consecutive annual increase), and €4.12 for FY2025 (a 5% rise, the 31st consecutive increase, proposed for approval at the 2026 AGM) (Q4 2024 6-K; Q4 2025 call, Jan 29 2026). A 31-year unbroken streak of increases is a strong, durable signal of a dividend-committed culture.

Buybacks and dilution. Sanofi has run consistent repurchase programs: a €2 billion authorization at the April 2024 AGM (executed through 2024-25), and a €5 billion program for 2025 - the latter notably including a €3 billion related-party block purchase of 29.56 million shares from historical shareholder L'Oréal at €101.50 in February 2025 (shares cancelled), plus a €2 billion open-market mandate running Feb-Dec 2025 (L'Oréal/Sanofi agreement, Feb 3 2025; Q4 2024 6-K). For 2026 management announced a smaller €1 billion buyback. Most repurchased shares are cancelled rather than warehoused, so the share count has been trending down rather than up - the L'Oréal block alone retired ~2.3% of capital. (The 2026 step-down to €1 billion reflects ~€14-15 billion of firepower being reserved for M&A rather than reduced commitment to returns.)

Verdict: Returns Capital - a 31-year dividend-growth streak plus multi-billion, mostly-cancelled buybacks make this a clearly shareholder-return-friendly company, with the only caveat that 2026 buyback scale was deliberately reduced to fund acquisitions.

Section 11: Insider Activities

Venue and source note. Sanofi is listed on Euronext Paris (SAN.PA) with a US ADR (NASDAQ: SNY). Director/officer dealings fall under EU Market Abuse Regulation Article 19 and are filed to the French regulator AMF ("déclarations de dirigeants"). I attempted to retrieve the AMF managers'-transactions register directly; the AMF database is a JavaScript portal that did not return queryable per-issuer results within the search budget, and web search surfaced SEC 6-K filings rather than individual PDMR notices. Individual director-level open-market buy/sell PDMR filings for Sanofi over the last 12 months could not be confirmed from a primary source within the search budget. I therefore report the material, primary-source-verified ownership transactions and disclose the gap rather than fabricate director-level trades.

Material transactions (most recent first):

Buys - read the signal. No confirmed open-market insider purchases by Sanofi directors or officers were located in the period. The absence of a confirmed cluster-buy signal should be read as "not found / not disclosed within budget," not as evidence that none occurred.

Sells - work out the why. The one large, clearly material transaction is L'Oréal trimming its long-held Sanofi stake by 2.3% in February 2025. The reason is explicitly disclosed and is not a view on Sanofi's prospects: L'Oréal stated the sale was to "optimize its balance sheet, notably following its recent acquisitions, and further diversify the Group's financing sources" (L'Oréal press release, Feb 3 2025). It was structured as a buyback by Sanofi (shares cancelled), so it doubled as capital return rather than a market overhang. L'Oréal remains one of Sanofi's largest shareholders at 7.2%/13.1% voting. The other major personnel event of the window - Paul Hudson's departure as CEO in February 2026 - was a board action, not an insider trade.

Net assessment. The only verified material ownership move is a long-standing strategic holder (L'Oréal) modestly trimming for its own balance-sheet reasons, executed as a value-neutral cancellation-buyback rather than a bearish signal. No confirmed insider open-market buying or selling cluster was identified. The honest read on this section is neutral, with low signal - the most consequential insider event was the board's removal of the CEO, which carries strategic rather than transactional information. A reader who wants a definitive director-dealings picture should consult the AMF "déclarations de dirigeants" register directly for Sanofi (ISIN FR0000120578).

Section 12: Scenarios

Bull case. Belén Garijo arrives, keeps the parts of Hudson's strategy that were working, and sharpens capital discipline - exactly the combination the board wanted. Dupixent's ninth indication (allergic fungal rhinosinusitis) clears, and the franchise keeps compounding through the late 2020s while the second wave arrives on schedule: amlitelimab launches into atopic dermatitis as a genuinely differentiated monthly/quarterly biologic and builds toward blockbuster scale, while the 2025 launch class (ALTUVIIIO, Ayvakit, Qfitlia, Wayrilz) matures into a multi-billion-euro portfolio that diversifies the company away from single-product dependence. The €14-15 billion M&A war chest is spent well, bolting on assets that thicken the early-2030s revenue bridge. Vaccines stabilize, Beyfortus extends its infant-RSV lead, and the Dynavax and Novavax additions broaden the franchise. By 2028-2029 Sanofi has visibly de-risked the Dupixent cliff, margins have expanded on specialty mix, the dividend streak rolls past 33 years, and the market re-rates the strategic credibility that the financials always supported.

Base case. Garijo runs the playbook roughly as guided. 2026 delivers high-single-digit sales growth and slightly faster EPS, as management promised on the Q4 2025 call, with Q1 2026's +13.6% start providing a cushion. Dupixent keeps growing but decelerates as it matures; the launch portfolio ramps steadily; amlitelimab succeeds commercially but takes time to scale. Vaccines are flat-to-slightly-down as flagged, with flu and COVID volatility offsetting Beyfortus. The pipeline produces the usual mix - some wins, some tolebrutinib-style misses - and the company continues bolt-on M&A. The Dupixent cliff remains the looming question, partially but not fully answered. Capital return continues (rising dividend, modest buyback). The business compounds respectably; the strategic verdict on whether the next Dupixent has truly been found stays open into the late 2020s.

Bear case. The CEO change proves disruptive rather than clarifying. Garijo rebases guidance, takes impairments on Hudson-era bets, or pivots strategy in a way that interrupts momentum. The second wave disappoints where it matters: amlitelimab underwhelms commercially against Lilly's Ebglyss and the oral JAKs, another high-profile Phase 3 fails the way tolebrutinib did, and the launch portfolio plateaus below expectations. Then the early-2030s Dupixent patent cliff arrives with the replacement revenue still short, and a third of the company's sales begin eroding to biosimilars faster than the pipeline can backfill. US drug-pricing politics (IRA negotiation reaching a major product) or pharmaceutical tariffs compress the most profitable region. Vaccines stay volatile. Expensive M&A done under pressure to plug the gap destroys value. The dividend streak survives but growth stalls, and Sanofi looks like a company that spent a decade and a fortune searching for the next Dupixent and did not find it in time.

Sources

• Sanofi Q1 2026 press release (6-K)
• Sanofi Q4/FY2025 earnings call (Jan 29 2026)
• Sanofi Q3 2025 press release (6-K) · Q3 2025 transcript (MarketScreener)
• Sanofi Q2/H1 2025 press release (6-K) · H1 2025 management report
• Sanofi Q1 2025 press release (6-K)
• Sanofi Q4/FY2024 press release (6-K) · Q4 2024 transcript (MarketScreener)
• Sanofi & CD&R close Opella transaction (Apr 30 2025)
• Sanofi CEO change - Hudson replaced by Garijo (STAT, Feb 12 2026) · CNBC
• L'Oréal / Sanofi share repurchase agreement (Feb 3 2025)
• Sanofi pipeline page (April 2026)
• Peer market caps: Largest healthcare companies 2026 (Motley Fool), companiesmarketcap.com

(Section 13 / Further Reading omitted: no qualifying in-depth Sanofi coverage was found from SemiAnalysis, Stratechery, or MBI Deep Dives - these are tech/semiconductor/equity-research voices and none had a Sanofi-centric piece.)

A note on delivery: This environment exposes only web tools, so I could not write the .md file or render the charts to disk directly. Copy the report above into Sanofi_SNY_DeepDive.md and the chart-data block will render in your harness's chart pipeline. If you'd like, I can also produce the insider section more completely if you can point me at an accessible AMF "déclarations de dirigeants" export for ISIN FR0000120578.